Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06914648 · ClinicalTrials.gov registry record · NA
The Dragon PLC Trial (DRAGON-PLC)
A NA study of Cholangiocarcinoma and Hepatocellular Carcinoma (HCC), sponsored by Maastricht University.
- Recruiting
- Registry status
- NA
- Development phase
- 358
- Enrollment target
- 20
- Study locations
NCT06914648 is a NA study of Cholangiocarcinoma and Hepatocellular Carcinoma (HCC) that is actively recruiting participants, run by Maastricht University. The registered enrollment target is 358 participants, roughly in line with the 380-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target. The trial reports 20 study locations across 15 states.
The verdict
NCT06914648, a NA study of Cholangiocarcinoma and Hepatocellular Carcinoma (HCC), is actively recruiting participants, sponsored by Maastricht University.
- RECRUITING
- Registry status
- NA
- Development phase
- 358 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specifically focuses on patients with hepatocellular carcinoma and cholangiocarcinoma. The main questions this trial aims to answer are whether combined PVE and HVE increases the proportion of patients who become resectable within 3 weeks and improves 5-year overall survival compared to PVE alone by enhancing liver hypertrophy. Participants will: * Undergo either standard PVE or combined PVE and HVE. * Have regular imaging to assess liver resectability. * Be monitored for survival outcomes up to 5 years after intervention.
Conditions Studied
Interventions
- PROCEDURE Portal Vein Embolization
- PROCEDURE Hepatic Vein Embolization
Study Locations (20)
Other
- Monash Medical Center - Melbourne
- Cliniques Universitaires Saint Luc, UCLouvain - Brussels
- Jessa Hospital - Hasselt
- UZ Brussel - Jette
- AZ Groeninge Hospital Kortrijk - Kortrijk
Vienna
- Medical University of Vienna - Vienna
- Social Center South - Vienna
Connecticut
- Yale School of Medicine Hospital - New Haven
Illinois
- Rush University Medical Center - Chicago
Minnesota
- Mayo Clinic - Rochester
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cleveland Clinic - Cleveland
Brussels Capital
- Erasmus Hospital - Brussels
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2032-11-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06914648
The ClinicalTrials.gov registry entry for NCT06914648 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 358 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 380-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target. The listed sponsor is Maastricht University, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Portal Vein Embolization is the first listed.
NCT06914648 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Vienna, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06914648 about?
NCT06914648 is a clinical study titled "The Dragon PLC Trial (DRAGON-PLC)". The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specifica...
What is the current status of trial NCT06914648?
This trial is currently recruiting. It is a NA study. The enrollment target is 358 participants. The study started on 2025-04-01. Estimated completion is 2032-11-15.
What conditions does trial NCT06914648 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Hepatocellular Carcinoma (HCC), Primary Liver Cancer.
What interventions are being tested in trial NCT06914648?
The interventions under investigation include: Portal Vein Embolization (PROCEDURE), Hepatic Vein Embolization (PROCEDURE).
Who is sponsoring clinical trial NCT06914648?
This trial is sponsored by Maastricht University, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06914648 being conducted?
This trial has 20 study locations across Connecticut, Illinois, Minnesota, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
RECRUITING · NA
-
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
RECRUITING · NA
-
Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid
RECRUITING · NA
-
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.